CLINICAL_TRIALS
ClinicalTrials.gov record update
Anlotinib Plus Nab-Paclitaxels and S-1 Versus FOLFOX for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment: a Phase 2/3, Multi-centric Double-stage Randomized Controlled Trial
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT06662877
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:27:10.540264+00:00
- Published At
- 2024-10-29T00:00:00+00:00
- Record Updated At
- 2024-10-29
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Biliary Tract Cancer", "Second Line Treatment", "Chemotherapy", "Tyrosine Kinase Inhibitor"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-10-29"- protocolSection.identificationModule.nctId
"NCT06662877"- protocolSection.identificationModule.officialTitle
"Anlotinib Plus Nab-Paclitaxels and S-1 Versus FOLFOX for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment: a Phase 2/3, Multi-centric Double-stage Randomized Controlled Trial"- protocolSection.statusModule.overallStatus
"NOT_YET_RECRUITING"- protocolSection.designModule.phases
["PHASE2", "PHASE3"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.